BXRX.OQ
Latest Trade
1.46USDChange
-0.11(-7.01%)Volume
1,193,342Today's Range
-
1.5252 Week Range
-
10.12As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 1.57 |
|---|---|
Open | 1.51 |
Volume | 1,193,342 |
3M AVG Volume | 72.12 |
Today's High | 1.52 |
Today's Low | 1.40 |
52 Week High | 10.12 |
52 Week Low | 0.97 |
Shares Out (MIL) | 42.64 |
Market Cap (MIL) | 66.94 |
Forward P/E | -0.38 |
Dividend (Yield %) | -- |
Baudax Bio Reports Third Quarter 2020 Financial Results
Baudax Bio Reports Qtrly Loss Per Share $1.72
Baudax Bio Q2 Loss Per Share $1.72 Including Items
Baudax Bio, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The Company’s lead product candidate is IV injectable form of Meloxicam, a long-acting preferential cyclooxygenase (COX)-2 inhibitor. The Company’s product pipeline also includes other early-stage product candidates, including two neuromuscular blocker agents (NMBAs) and a related chemical reversal agent, and Dexmedetomidine (Dex)- intranasal (IN), an intranasal formulation of dexmedetomidine. The Company is developing an intermediate-acting NMBA, RP100; an ultrashort-acting NMBA, RP2000, and a reversal agent specific to its NMBAs.
Industry
Biotechnology & Drugs
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 160.53 |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -183.60 |
Return on Equity (TTM) | -136.24 |
* BAUDAX BIO - RECEIPT OF UNIQUE C-CODE AND PASS-THROUGH PAYMENT STATUS EFFECTIVE JULY 1 Source text for Eikon: Further company coverage:
* BAUDAX BIO SECURES $50 MILLION CREDIT FACILITY Source text for Eikon: Further company coverage:
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on Monday. HIGHLIGHTS * Acushnet Holdings Corp : Stephens raises target price to $27 from $24 * Equity Residential...
* STONEPINE CAPITAL MANAGEMENT LLC REPORTS 9.99% PASSIVE STAKE IN BAUDAX BIO INC AS OF MARCH 24 - SEC FILING Source text: (http://www.sec.gov/Archives/edgar/data/1440771/000093583620000245/0000935836-20-000245-index.htm) Further company coverage:
* BAUDAX BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS
* BAUDAX BIO - SIGNED A NON-BINDING TERM SHEET WITH AN UNDISCLOSED PARTY FOR A SECURED TERM LOAN FOR UP TO $20 MILLION IN NON-DILUTIVE FUNDING
* BAUDAX BIO ANNOUNCES FDA APPROVAL OF ANJESO™ FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN
* BAUDAX BIO - MAY OFFER, SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $25 MILLION FROM TIME TO TIME - SEC FILING Source text: (http://bit.ly/2uMpgmG) Further company coverage:
* BAUDAX BIO INC - AS OF DECEMBER 31, 2019, BAUDAX HAD CASH AND CASH EQUIVALENTS OF $17.7 MILLION Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.